Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EN3348 versus mitomycin C for BCG-recurrent or BCG-refractory non-muscle invasive bladder cancer
NL-OMON35360Phase 3Withdrawn
- Sponsor
- Endo International plc
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma (TCC) comparing EN3348 with Mitomycin C (2 arms). Primary endpoints: Event-free survival and Safety. Planned start Feb 2012; status: withdrawn.
02
Drugs
mycobacterial cell wall-DNA complexmitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON35360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35360.